| Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a … GM Schroeder, Y An, ZW Cai, XT Chen, C Clark, LAM Cornelius, J Dai, ... Journal of medicinal chemistry 52 (5), 1251-1254, 2009 | 337 | 2009 |
| Ha-ras proteins exhibit GTPase activity: point mutations that activate Ha-ras gene products result in decreased GTPase activity. V Manne, E Bekesi, HF Kung Proceedings of the National Academy of Sciences 82 (2), 376-380, 1985 | 249 | 1985 |
| Identification and preliminary characterization of protein-cysteine farnesyltransferase. V Manne, D Roberts, A Tobin, E O'Rourke, M De Virgilio, C Meyers, ... Proceedings of the National Academy of Sciences 87 (19), 7541-7545, 1990 | 205 | 1990 |
| Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. V Manne, N Yan, JM Carboni, AV Tuomari, CS Ricca, JG Brown, ... Oncogene 10 (9), 1763-1779, 1995 | 202 | 1995 |
| Discovery of (R)-7-cyano-2, 3, 4, 5-tetrahydro-1-(1 H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1 H-1, 4-benzodiazepine (BMS-214662), a farnesyltransferase … JT Hunt, CZ Ding, R Batorsky, M Bednarz, R Bhide, Y Cho, S Chong, ... Journal of medicinal chemistry 43 (20), 3587-3595, 2000 | 180 | 2000 |
| Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors MR Lackner, RM Kindt, PM Carroll, K Brown, MR Cancilla, C Chen, ... Cancer cell 7 (4), 325-336, 2005 | 168 | 2005 |
| Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype N Yan, C Ricca, J Fletcher, T Glover, BR Seizinger, V Manne Cancer research 55 (16), 3569-3575, 1995 | 154 | 1995 |
| Discovery of pyrrolopyridine− pyridone based inhibitors of Met kinase: Synthesis, X-ray crystallographic analysis, and biological activities KS Kim, L Zhang, R Schmidt, ZW Cai, D Wei, DK Williams, LJ Lombardo, ... Journal of medicinal chemistry 51 (17), 5330-5341, 2008 | 140 | 2008 |
| Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor WC Rose, FYF Lee, CR Fairchild, M Lynch, T Monticello, RA Kramer, ... Cancer research 61 (20), 7507-7517, 2001 | 139 | 2001 |
| Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase JT Hunt, VG Lee, K Leftheris, B Seizinger, J Carboni, J Mabus, C Ricca, ... Journal of medicinal chemistry 39 (2), 353-358, 1996 | 127 | 1996 |
| Mechanism of translational control by partial phosphorylation of the alpha subunit of eukaryotic initiation factor 2. J Siekierka, V Manne, S Ochoa Proceedings of the National Academy of Sciences 81 (2), 352-356, 1984 | 124 | 1984 |
| Farnesyl diphosphate-based inhibitors of Ras farnesyl protein transferase DV Patel, RJ Schmidt, SA Biller, EM Gordon, SS Robinson, V Manne Journal of medicinal chemistry 38 (15), 2906-2921, 1995 | 122 | 1995 |
| Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity K Leftheris, T Kline, GD Vite, YH Cho, RS Bhide, DV Patel, MM Patel, ... Journal of medicinal chemistry 39 (1), 224-236, 1996 | 102 | 1996 |
| Ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase V Manne, CS Ricca, JG Brown, AV Tuomari, N Yan, D Patel, R Schmidt, ... Drug development research 34 (2), 121-137, 1995 | 98 | 1995 |
| Phosphinyl acid-based bisubstrate analog inhibitors of farnesyl protein transferase DV Patel, EM Gordon, RJ Schmidt, HN Weller, MG Young, R Zahler, ... Journal of medicinal chemistry 38 (3), 435-442, 1995 | 94 | 1995 |
| Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt–induced hypertension MM Muthalif, IF Benter, Z Khandekar, L Gaber, A Estes, S Malik, ... Hypertension 35 (1), 457-463, 2000 | 86 | 2000 |
| Guanosine nucleotide binding by highly purified Ha-ras-encoded p21 protein produced in Escherichia coli. V Manne, S Yamazaki, HF Kung Proceedings of the National Academy of Sciences 81 (22), 6953-6957, 1984 | 85 | 1984 |
| Reversal of transformed phenotype by monoclonal antibodies against Ha-ras p21 proteins HF Kung, MR Smith, E Bekesi, V Manne, DW Stacey Experimental cell research 162 (2), 363-371, 1986 | 82 | 1986 |
| Discovery of orally active pyrrolopyridine-and aminopyridine-based Met kinase inhibitors ZW Cai, D Wei, GM Schroeder, LAM Cornelius, K Kim, XT Chen, ... Bioorganic & medicinal chemistry letters 18 (11), 3224-3229, 2008 | 81 | 2008 |
| Identification of pyrrolo [2, 1-f][1, 2, 4] triazine-based inhibitors of Met kinase GM Schroeder, XT Chen, DK Williams, DS Nirschl, ZW Cai, D Wei, ... Bioorganic & medicinal chemistry letters 18 (6), 1945-1951, 2008 | 70 | 2008 |
